



Press Release

Theralase Commissioned by European Pharmaceutical Company to Contract Manufacture Prototype PDT Light-Based Systems

For Immediate Release

TORONTO, ONTARIO, April 8, 2008 - Theralase Technologies Inc. (TSX-V: TLT), a designer, manufacturer and distributor of therapeutic medical laser and light-based systems, today announced that a European pharmaceutical company has commissioned Theralase to contract manufacture ten beta prototype photodynamic therapy (PDT) light-based systems for delivery in the second and third quarter of 2008.

Theralase was initially chosen by the European pharmaceutical company to manufacture a beta prototype PDT light-based system to be used in combination with the European pharmaceutical company's proprietary photosensitisers (light sensitive compounds). The original beta prototype PDT light-based system was approved by the European pharmaceutical company on March 14, 2008, subject to minor modifications.

"Contract manufacturing PDT light-based systems for a global player represents an exciting opportunity for Theralase to extend its market reach," said Roger Dumoulin-White, President & CEO of Theralase. "Theralase looks forward to building a strong strategic relationship with the European pharmaceutical company."

About Theralase

Theralase Technologies Inc. designs, manufactures and distributes patented, super-pulsed laser and light-based technology systems used in a wide range of therapeutic clinical applications. The Theralase technology platform has been proven clinically effective in non-invasive pain management and clinical therapy, including hundreds of different neural muscular skeletal conditions such as sports injuries, repetitive strain injuries and arthritis.

Visit the Theralase website at www.theralase.com for more detailed information on the Company's products and research.

Contact information: Roger Dumoulin-White, Theralase Technologies Inc., President & CEO, (416) 447-8455, rwhite@theralase.com; Vanessa Beresford, The Equicom Group Inc., (416) 815 0700, ext 227, vberesford@equicomgroup.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this release.